| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 3907 |
Provisional Schedule
| Expected publication | 11 December 2024 |
Project Team
| Project lead | Celia Mayers |
Email enquiries
- If you have any queries please email TATeam6@nice.org.uk
| External Assessment Group | BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors | Merck Sharp & Dohme (pembrolizumab) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Roy Castle Lung Cancer Foundation |
| Professional groups | Association of Cancer Physicians |
| British Thoracic Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Aspire Pharma (pemetrexed) – confidentiality agreement not signed, not participating |
| AstraZeneca (durvalumab, osimertinib) | |
| Bristol Myers Squibb (paclitaxel) | |
| Eli Lilly (pemetrexed) – confidentiality agreement not signed, not participating | |
| Genus Pharmaceuticals (pemetrexed) – confidentiality agreement not signed, not participating | |
| Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) – confidentiality agreement not signed, not participating | |
| Medac (vinorelbine) – confidentiality agreement not signed, not participating | |
| Pfizer (pemetrexed) – confidentiality agreement not signed, not participating | |
| Pierre Fabre (vinorelbine) – confidentiality agreement not signed, not participating | |
| Roche (atezolizumab) | |
| Sandoz (cisplatin, pemetrexed) – confidentiality agreement not signed, not participating | |
| Seacross Pharmaceuticals (docetaxel, pemetrexed, paclitaxel) – confidentiality agreement not signed, not participating | |
| Sun Pharma (gemcitabine) – confidentiality agreement not signed, not participating | |
| Synchrony Pharma (gemcitabine) – confidentiality agreement not signed, not participating | |
| Teva UK (paclitaxel) – confidentiality agreement not signed, not participating | |
| Zentiva (pemetrexed) – confidentiality agreement not signed, not participating | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 October 2024 | Committee meeting: 2 |
| 03 October 2024 | Declaration of interests |
| 29 August 2024 - 19 September 2024 | Draft guidance |
| 07 August 2024 | Committee meeting |
| 09 January 2024 | Invitation to participate |
| 25 August 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in January 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission. |
| 18 July 2023 | The scope of the first iteration of the NSCLC pathway will focus on development of the evidence synthesis of currently available data and the core model development. Therefore, ID3907, will be routed through a single technology appraisal route. More details about the NSCLC can be found on the webpage for ID6234. |
| 27 February 2023 | Please note that the evaluation of pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer ID3907, will now be conducted via ID6234 considering multiple treatments for non-small-cell lung cancer. |
| 16 December 2022 | Please note that following on from a further regulatory update received from the company, the timelines for this appraisal have been revised. |
| 14 September 2022 | Please note that following on from a regulatory update received from the company, the timelines for this appraisal have been revised. |
| 14 July 2022 | Invitation to participate |
| 13 April 2022 - 13 May 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 January 2022 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual